Response to Y. Sasaki et al.: Is repeating FOLFIRINOX in the original dosage and treatment schedule tolerable in Japanese patients with pancreatic cancer?

Detalles Bibliográficos
Autores principales: Okusaka, Takuji, Ikeda, Masafumi, Fukutomi, Akira, Ioka, Tatsuya, Furuse, Junji, Ohkawa, Shinichi, Isayama, Hiroyuki, Boku, Narikazu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Ltd 2015
Materias:
Letters to the Editor
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4556402/
https://www.ncbi.nlm.nih.gov/pubmed/26268894
http://dx.doi.org/10.1111/cas.12709
_version_ 1782388344948260864
author Okusaka, Takuji
Ikeda, Masafumi
Fukutomi, Akira
Ioka, Tatsuya
Furuse, Junji
Ohkawa, Shinichi
Isayama, Hiroyuki
Boku, Narikazu
author_facet Okusaka, Takuji
Ikeda, Masafumi
Fukutomi, Akira
Ioka, Tatsuya
Furuse, Junji
Ohkawa, Shinichi
Isayama, Hiroyuki
Boku, Narikazu
author_sort Okusaka, Takuji
collection PubMed
description
format Online
Article
Text
id pubmed-4556402
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher John Wiley & Sons, Ltd
record_format MEDLINE/PubMed
spelling pubmed-45564022015-10-05 Response to Y. Sasaki et al.: Is repeating FOLFIRINOX in the original dosage and treatment schedule tolerable in Japanese patients with pancreatic cancer? Okusaka, Takuji Ikeda, Masafumi Fukutomi, Akira Ioka, Tatsuya Furuse, Junji Ohkawa, Shinichi Isayama, Hiroyuki Boku, Narikazu Cancer Sci Letters to the Editor John Wiley & Sons, Ltd 2015-08 2015-08-12 /pmc/articles/PMC4556402/ /pubmed/26268894 http://dx.doi.org/10.1111/cas.12709 Text en © 2015 The Authors. Cancer Science published by Wiley Publishing Asia Pty Ltd on behalf of Japanese Cancer Association. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
spellingShingle Letters to the Editor
Okusaka, Takuji
Ikeda, Masafumi
Fukutomi, Akira
Ioka, Tatsuya
Furuse, Junji
Ohkawa, Shinichi
Isayama, Hiroyuki
Boku, Narikazu
Response to Y. Sasaki et al.: Is repeating FOLFIRINOX in the original dosage and treatment schedule tolerable in Japanese patients with pancreatic cancer?
title Response to Y. Sasaki et al.: Is repeating FOLFIRINOX in the original dosage and treatment schedule tolerable in Japanese patients with pancreatic cancer?
title_full Response to Y. Sasaki et al.: Is repeating FOLFIRINOX in the original dosage and treatment schedule tolerable in Japanese patients with pancreatic cancer?
title_fullStr Response to Y. Sasaki et al.: Is repeating FOLFIRINOX in the original dosage and treatment schedule tolerable in Japanese patients with pancreatic cancer?
title_full_unstemmed Response to Y. Sasaki et al.: Is repeating FOLFIRINOX in the original dosage and treatment schedule tolerable in Japanese patients with pancreatic cancer?
title_short Response to Y. Sasaki et al.: Is repeating FOLFIRINOX in the original dosage and treatment schedule tolerable in Japanese patients with pancreatic cancer?
title_sort response to y. sasaki et al.: is repeating folfirinox in the original dosage and treatment schedule tolerable in japanese patients with pancreatic cancer?
topic Letters to the Editor
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4556402/
https://www.ncbi.nlm.nih.gov/pubmed/26268894
http://dx.doi.org/10.1111/cas.12709
work_keys_str_mv AT okusakatakuji responsetoysasakietalisrepeatingfolfirinoxintheoriginaldosageandtreatmentscheduletolerableinjapanesepatientswithpancreaticcancer
AT ikedamasafumi responsetoysasakietalisrepeatingfolfirinoxintheoriginaldosageandtreatmentscheduletolerableinjapanesepatientswithpancreaticcancer
AT fukutomiakira responsetoysasakietalisrepeatingfolfirinoxintheoriginaldosageandtreatmentscheduletolerableinjapanesepatientswithpancreaticcancer
AT iokatatsuya responsetoysasakietalisrepeatingfolfirinoxintheoriginaldosageandtreatmentscheduletolerableinjapanesepatientswithpancreaticcancer
AT furusejunji responsetoysasakietalisrepeatingfolfirinoxintheoriginaldosageandtreatmentscheduletolerableinjapanesepatientswithpancreaticcancer
AT ohkawashinichi responsetoysasakietalisrepeatingfolfirinoxintheoriginaldosageandtreatmentscheduletolerableinjapanesepatientswithpancreaticcancer
AT isayamahiroyuki responsetoysasakietalisrepeatingfolfirinoxintheoriginaldosageandtreatmentscheduletolerableinjapanesepatientswithpancreaticcancer
AT bokunarikazu responsetoysasakietalisrepeatingfolfirinoxintheoriginaldosageandtreatmentscheduletolerableinjapanesepatientswithpancreaticcancer

Ejemplares similares